Drugs / MF59
Trials 15 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 11 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07421050 Background | Nov 2025 → Dec 2026 expected | influenza | Ab&B Bio-tech Co., Ltd.JS | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07421037 Background | Nov 2025 → Dec 2026 expected | influenza | Ab&B Bio-tech Co., Ltd.JS | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01418235 Background | Dec 2011 → Oct 2013 | — | HIV Vaccine Trials Network | Completed | No outcome recorded |
| Phase 1 | NCT00848848 Comparator | Oct 2008 → Apr 2009 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 1 | NCT00000832 Background | ? → Jan 1998 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000868 Background | ? → May 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03284710 Comparator | Jun 2017 → Dec 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02213354 Background | Oct 2014 → Jul 2016 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01097096 Comparator | Mar 2010 → Dec 2012 | Alzheimer disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00133497 Background | Jun 2006 → Jun 2013 | cytomegalovirus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00125502 Background | Aug 1999 → Jun 2007 | cytomegalovirus infection | Robert Pass, MD | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-09-26 | CSL Behring | New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems csl.com ↗ |
| 2020-12-14 | CSL Behring | Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Value of MF59®-Adjuvanted Seasonal Influenza Vaccine csl.com ↗ |
| 2019-08-30 | CSL Behring | Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response csl.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MF59 | “3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22.” NCT03682120 ↗28“MF59®-adjuvanted influenza vaccines have superior immunogenicity in older adults compared with non-adjuvanted vaccines” PMID 22426371 ↗ Feb 2012 “7.5 mcg Influenza A (H7N9) with MF59® Injection” NCT06417853 ↗ “Microfluoridized adjuvant 59 (MF59).” NCT00133497 ↗ “MF59 adjuvant” NCT00912496 ↗ “MF59” NCT01097096 ↗ |
| Known as | MF59(R) | “3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22.” NCT03682120 ↗ |
| Modality | Other / unclassified | “MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines” PMID 24732325 ↗ Apr 2014 |
| Route | Intramuscular | “Healthy volunteers receive intramuscular injections of rgp120/HIV-1SF2 with MF59 adjuvant emulsion or MF59 alone at months 0, 1, 6, 9, 10 and 12” NCT00000832 ↗ |